15 completed, 2 terminated, 1 active not recruiting. 8 Phase 2, 5 Phase 1, 4 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 5 | Completed 3, Terminated 2 |
| Not applicable | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Primary Systemic Amyloidosis: new trials by email Literature Review of Primary Systemic Amyloidosis trials Research Report on Primary Systemic Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial Doxycycline - Primary Systemic Amyloidosis | Phase 2 | Completed | Medical College of Wisconsin | 32 | 2014-10-01 | 2021-07-09 |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma dexamethasone, cisplatin, doxorubicin - Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone | Phase 2 | Completed | Margarida Magalhaes-Silverman | 41 | 2013-04-04 | 2022-05-11 |
| First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD pomalidomide, bortezomib, dexamethasone - Light Chain Deposition Disease, Primary Systemic Amyloidosis | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 18 | 2013-03-01 | 2023-05-09 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis melphalan, dexamethasone, bortezomib - Light Chain Deposition Disease, Primary Systemic Amyloidosis | Phase 3 | Completed | National Cancer Institute (NCI) | 11 | 2010-11-01 | 2022-02-01 |
| Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Lenalidomide, Cyclophosphamide, Dexamethasone - Primary Systemic Amyloidosis | Phase 2 | Completed | PETHEMA Foundation | 30 | 2010-10-01 | 2017-04-25 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis bortezomib, cyclophosphamide, dexamethasone - Primary Systemic Amyloidosis | Phase 2 | Completed | Mayo Clinic | 2 | 2010-03-01 | 2014-04-02 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease bortezomib, dexamethasone, melphalan - Primary Systemic Amyloidosis, Light Chain Deposition Disease | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 35 | 2007-09-01 | 2023-12-22 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors etoposide, cyclophosphamide, carmustine - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Not applicable | Completed | Roswell Park Cancer Institute | 174 | 2006-06-29 | 2021-04-22 |
| Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis 4'-iodo-4'-deoxydoxorubicin, pharmacological study - Primary Systemic Amyloidosis | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2001-12-01 | 2013-01-16 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2001-08-01 | 2013-02-07 |
| Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis Enbrel - Primary Systemic Amyloidosis | Phase 2 | Completed | The Cleveland Clinic | 60 | 2001-02-01 | 2023-05-30 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation - Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia | Not applicable | Completed | Fred Hutchinson Cancer Center | 160 | 2000-12-01 | 2020-01-21 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Fred Hutchinson Cancer Center | 5 | 1999-11-01 | 2017-05-24 |
Immunoglobulin Light-chain Amyloidosis (18) · Multiple Myeloma (9) · Burkitt Lymphoma (8) · Intraocular Lymphoma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Large-Cell, Anaplastic (8) · Lymphoma, T-Cell, Cutaneous (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Hodgkin Disease (7) · Immunoblastic Lymphadenopathy (7) · Leukemia, Biphenotypic, Acute (7) · Leukemia, Large Granular Lymphocytic (7) · Leukemia, Myelomonocytic, Chronic (7) · Lymphoma, B-Cell, Marginal Zone (7)
Immune System Diseases (18) · Immunoproliferative Disorders (18) · Lymphoproliferative Disorders (18) · Metabolic Diseases (18) · Neoplasms (18) · Neoplasms by Histologic Type (18) · Nutritional and Metabolic Diseases (18) · Paraproteinemias (18) · Proteostasis Deficiencies (18) · Neoplasms, Plasma Cell (16) · Amyloidosis (14) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Blood Protein Disorders (9) · Cardiovascular Diseases (9)
Dexamethasone (6) · Bortezomib (5) · Calcium Dobesilate (5) · Cyclophosphamide (4) · Melphalan (4) · Whole-Body Irradiation (4) · Cyclosporine (3) · Mycophenolic Acid (3) · Peripheral Blood Stem Cell Transplantation (3) · fludarabine phosphate (3) · Etoposide (2) · Flow Cytometry (2) · 4'-deoxy-4'-iododoxorubicin (1) · Antiviral Agents (1) · Busulfan (1)
National Cancer Institute (NCI) (4) · Fred Hutchinson Cancer Center (3) · Barbara Ann Karmanos Cancer Institute (2) · City of Hope Medical Center (1) · Margarida Magalhaes-Silverman (1) · Mayo Clinic (1) · Medical College of Wisconsin (1) · PETHEMA Foundation (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · The Cleveland Clinic (1) · Wake Forest University Health Sciences (1)
United States (16) · Italy (2) · Canada (1) · Germany (1) · Spain (1)
David Maloney (2) · Angela Dispenzieri (1) · Angela Dispenzieri, M.D. (1) · Anita D'Souza, MD (1) · Ann Woolfrey (1) · Emma Scott (1) · Janet Tooze, PhD (1) · Jeffrey A. Zonder, MD (1) · Jeffrey Zonder (1) · John A Lust, MD, PhD (1) · John Deeken (1) · Margarida Magalhaes-Silverman, MD (1) · Mohamad A Hussein, MD (1) · Philip McCarthy (1)
PMID 32499241, PMID 18698002, PMID 22259028, PMID 24474568, PMID 25974382, PMID 32529175, PMID 40925099
P30CA015704 (3), 2009 (1), K23HL141445 (1), KL2TR001438 (1), P01CA018029 (1), P01CA078902 (1), P30CA016056 (1), P30CA022453 (1), P30CA086862 (1), U01CA062487 (1), U01CA062491 (1), U01CA062502 (1), U01CA062505 (1), U01CA069912 (1), U01CA099168 (1)